Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Peter Ternus

Podiatrist San Leandro, CA Doctor of Podiatric Medicine

NPI 1790777019 CMS profile 955284

13847 E 14Th St Ste 210, Ste 210, San Leandro, CA 94578

Open in the dashboard

General payments

$6,399

88 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Peter Ternus of San Leandro, CA is reported in the CMS Open Payments database as having received $6,399 across 88 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $469 15
2024 General $477 10
2023 General $159 6
2022 General $1,579 14
2021 General $1,470 8
2020 General $1,188 11
2019 General $1,057 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Ternus
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Peter Ternus were reported at $469. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Peter Ternus Podiatrist median Middle half National median
2019 $1,057 $196 $72–$601 $163
2020 $1,188 $118 $38–$335 $114
2021 $1,470 $169 $57–$573 $132
2022 $1,579 $220 $74–$782 $149
2023 $159 $208 $71–$635 $160
2024 $477 $237 $87–$681 $164
2025 $469 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Evolution Surgical, Inc $4,047 10 payments
  2. Smith+Nephew, Inc. $703 33 payments
  3. Bioventus LLC $353 4 payments
  4. Access Pro Medical, LLC $234 7 payments
  5. Organogenesis Inc. $176 3 payments
  6. Medline Industries, Inc. $172 5 payments
  7. Treace Medical Concepts, Inc. $171 8 payments
  8. DePuy Synthes Sales Inc. $169 4 payments
  9. Musculoskeletal Transplant Foundation Inc. $78 1 payment
  10. Integra LifeSciences Corporation $68 2 payments
  11. Other $229 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $3,874 4 payments
  2. Food and Beverage $2,525 84 payments
Products named General payments · program years 2019–2025
  1. COLLAGENASE SANTYL $239 9 payments
  2. Matriderm $234 7 payments
  3. EXOGEN ULTRASOUND BONE HEALING SYSTEM $194 2 payments
  4. Hyalomatrix Wound Device $172 5 payments
  5. Affinity $125 1 payment
  6. LAPIPLASTY SYSTEM $117 6 payments
  7. GRAFIX PL $115 4 payments
  8. Stravix $106 3 payments
  9. Santyl $101 9 payments
  10. Grafix PL PRIME $98 4 payments
  11. Other $1,019 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

366

Median for Podiatry: 160

Drug cost

$7,022

Median for Podiatry: $2,368

Branded share of claims

3.8%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Colchicine Generic 13 $2,452
Gabapentin Generic 133 $1,852
Clotrimazole Generic 33 $726
Econazole Nitrate Generic 16 $441
Triamcinolone Acetonide Generic 22 $430
Diclofenac Sodium Generic 16 $391
Pregabalin Generic 17 $306
Meloxicam Generic 60 $158
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 14 $101
Cephalexin Generic 13 $81

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$164,458

Of which drugs: $1,441

Medicare patients

528

Average age 76

Services billed

2,101

306 women, 222 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 49%
Arthritis 47%
Chronic kidney disease 33%
Ischemic heart disease 24%
Heart failure 23%
Atrial fibrillation 21%
Depression 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 12 13 $73

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

88 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record